Use of peptide asparginyl ligases (PALs) in generating alternative non-Ig protein-drug conjugates for cancer therapy
Past research on antibody–drug conjugates (ADCs) focused on protein site-specific modification as chemical conjugation lacks site-selectivity. And despite monoclonal antibodies being the most common immunotherapeutic agent, its applicability & functionality are limited by several restrictions. T...
Saved in:
Main Author: | See, Julia Jing Yi |
---|---|
Other Authors: | Liu Chuan Fa |
Format: | Final Year Project |
Language: | English |
Published: |
Nanyang Technological University
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/167167 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
Similar Items
-
Expanding the ligation toolbox through protein engineering of peptide asparaginyl ligases (PALs)
by: Tan, Shaun Jun Hao
Published: (2023) -
Engineering of a peptide ligase from petunia exserta
by: Doong, Jing Yi
Published: (2021) -
On the design of a constitutively active peptide asparaginyl ligase for facile protein conjugation
by: Chua, Niying, et al.
Published: (2023) -
Development of antibody drug conjugates for cancer therapy
by: Alif Sufiyan Ali
Published: (2018) -
Ligase-controlled cyclo-oligomerization of peptides
by: Hemu, Xinya, et al.
Published: (2020)